This study involves patients with a nerve condition called peripheral anti-MAG neuropathy, which is a type of nerve damage that affects the arms and legs. This condition occurs when the body produces abnormal antibodies called anti-MAG antibodies that attack the protective coating around nerves. Patients in this study also have an underlying blood condition, which may be Waldenstrom macroglobulinemia, marginal zone lymphoma, chronic lymphocytic leukemia, or monoclonal gammopathy of unknown significance. These are conditions where certain white blood cells grow abnormally and produce abnormal proteins in the blood. The treatment being tested is zanubrutinib, also known by its code name BGB-3111, which is taken as a capsule by mouth. This medication works by blocking a specific protein in cells that helps the abnormal blood cells survive and produce the harmful antibodies.
The purpose of the study is to find out whether treatment with zanubrutinib for twelve months can lead to improvement in nerve function as measured by various scales that assess strength, sensation, and ability to perform daily activities. These scales help doctors understand how well patients can move, feel sensations, and carry out everyday tasks. The study will measure whether patients improve by at least one point on at least two of these measurement scales after one year of treatment.
During the study, patients will take zanubrutinib capsules daily for up to forty-eight months. The maximum daily amount is three hundred twenty milligrams, and the maximum total amount in a day is four hundred eighty milligrams. Doctors will regularly check nerve function using the measurement scales and will also perform nerve conduction studies, which are tests that measure how well electrical signals travel through the nerves. Blood tests will be done to measure the levels of abnormal proteins and anti-MAG antibodies at twelve, twenty-four, and forty-eight months to see if the treatment is reducing these harmful substances in the blood.



Italy